key: cord-0681819-2jed77mt authors: Stefanelli, P.; Trentini, F.; Guzzetta, G.; Marziano, V.; Mammone, A.; Poletti, P.; Molina Grane', C.; Manica, M.; del Manso, M.; Andrianou, X.; Pezzotti, P.; Ajelli, M.; Rezza, G.; Brusaferro, S.; Merler, S.; Group, COVID-19 National Microbiology Surveillance Study title: Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1 date: 2021-04-07 journal: nan DOI: 10.1101/2021.04.06.21254923 sha: 6c0cb8e811e6b9ec041899e5c6cf31b3bb29a1d2 doc_id: 681819 cord_uid: 2jed77mt SARS-CoV-2 variants of concern (B.1.1.7, P.1 and B.1.351) have emerged in different continents of the world. To date, little information is available on their ecological interactions. Based on two genomic surveillance surveys conducted on February 18 and March 18, 2021 across the whole Italian territory and covering over 3,000 clinical samples, we found significant co-circulation of B.1.1.7 and P.1. We showed that B.1.1.7 was already dominant on February 18 in a majority of regions/autonomous provinces (national prevalence 54%) and almost completely replaced historical lineages by March 18 (dominant in all regions/autonomous provinces, national prevalence 86%). At the same time, we found a substantial proportion of cases of the P.1 lineage on February 18, almost exclusively in Central Italy (with an overall prevalence in the macro-area of 18%), which remained at similar values on March 18, suggesting the inability by this lineage to outcompete B.1.1.7. Only 9 cases from variant B.1.351 were identified in the two surveys. At the national level, we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66). The relative transmissibility of P.1 estimated at the national level varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. These observations may have important consequences on the assessment of future pandemic scenarios. Since the end of 2020, multiple SARS-CoV-2 variants have emerged across the globe. Some of these are particularly concerning as their biological characteristics allowed them to outcompete and rapidly replace historical lineages in countries where they likely emerged, and to spread rapidly to many other countries. Variant B.1.1.7 was first detected in the United Kingdom from samples of September 2020 and was dominant throughout the country by early 2021 [1, 2] ; it has spread in most of Europe [3] and it has been reported in a majority of world countries [4, 5, 6] . Variant P.1 was first reported in Japan among travelers returning from Brazil [7] . It was later found in almost half of cases from December 2020 in Manaus, Brazil [8] where, despite a very high estimated seroprevalence against historical lineages [9] , a large upsurge of infections occurred throughout January 2021 [10] . B.1.351 was first detected in South Africa, where it is dominant since late November [11] . The epidemiological success of these variants relies on evolutionary advantages such as increased transmissibility [1, 2, 12] and their ability (demonstrated for P.1 and B.1.351) to significantly reduce neutralization in convalescent and post-vaccination sera [13, 14, 15, 16, 17] , likely resulting in reinfections through immune escape [18, 19, 20, 21] . Besides their greater ability to spread, requiring more restrictive physical distancing measures to mitigate epidemics, these variants cause additional concern due to potential increased morbidity [22] and mortality [23] (currently evaluated for B.1.1.7 only), as well as their potential impact on current vaccine effectiveness [24, 25] . Because variants seem to have emerged in disjoint geographical areas, little is known as yet about their ecological interactions. Here, we provide the first observation of significant co-circulation of variants B.1.1.7 and P.1 using data from genomic surveillance surveys in Italy. We use a mathematical model to estimate their relative transmissibility under different assumptions on the degree cross-protection. Survey methodology Two surveys coordinated by the Italian National Institute of Health (Istituto Superiore di Sanità), in collaboration with the Ministry of Health and the Regions/Autonomous Provinces (AP), aimed at estimating the prevalence of the B. Samples were uniformly distributed across 5 macro-areas, defined according to the Eurostat classification: North-East, North-West, Center, South and Islands. The sample size was calculated to have the statistical power to detect a prevalence of 1%, with 0,8% error within each macro-area, based on the number of cases notified on the day preceding each of the two surveys. The collected samples were sequenced according to the local laboratory policy by either of the following techniques: i) sequencing the entire S-gene by Sanger technology, ii) sequencing part of the S-gene with the identification of all mutations/deletions attributable to the three variants, or iii) sequencing the whole genome by Next Generation Sequencing. In the second survey, one region (Marche) pre-screened 54 of the 65 RT-PCR . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 7, 2021. ; positive samples using an in-house test that detects both H69-V70 and Y144 aminoacid deletions, which are specific for B.1.1.7; as a result, 46 cases positive to the in-house test were considered B.1.1.7 without sequencing. The 8 cases negative to the test, plus the 11 cases that were not pre-screened were sequenced. The point prevalence of the three lineages in each survey was computed as the fraction of infections attributable to each lineage among sequenced samples, and corresponding binomial 95% confidence intervals are provided. In the second survey, data from Marche were excluded from the analysis. SARS-CoV-2 three-strain transmission model We adopted a three-strain Susceptible -Infectious -Recovered (SIR) mathematical model to simulate co-circulation of historical lineages of SARS-CoV-2 ("wildtype") and variants of concern B.1.1.7 and P.1. We did not consider B.1.351 based on results from the surveys finding little or no circulation of this lineage (see Results). We assumed that a previous infection with the wildtype provides complete protection against variant B.1.1.7 [26] and that infection with either the wildtype or B.1.1.7 confers the same degree of cross-protection against P.1. In addition, we assumed that the transmissibility of variants B.1.1.7 and P.1 are scaled with respect to the wildtype transmissibility by a lineage-specific factor representing their relative transmissibility (k1 for B.1.1.7 and k2 for P.1). The three strains are assumed to have identical generation time (set at 6.6 days to reflect the serial interval estimated for SARS-CoV-2 in Italy [27] ). The model is initialized on January 15, 2021, assuming that an unknown fraction f1 and f2 of all infections at that date belongs to the B.1.1.7 and P.1 variant, respectively (see Appendix for full model details). Unknown model parameters (namely, the transmissibility of the wildtype strain , the relative transmissibility parameters of B.1.1.7 and P.1, k1 and k2, and their respective initial prevalence, f1 and f2) were estimated by calibrating the model against prevalence data from the two surveys (Table 1 and Where (⋅) is the multinomial probability density distribution; t is the date of the survey; ! % is the number of cases observed at date t for lineage ;, Qt is the total number of sequenced cases at date t; and ! % is the model-estimated fraction of infections of lineage over the total at date t. We assigned L=0 to simulations for which the model's mean squared error on the observed daily hospital admissions between January 18 and March 18, 2021 exceeded 1.5 times the variance of observations, in order to reproduce the observed epidemiological temporal trends. The model was run on 4 different geographical aggregations of regional data, i.e., the national level and the Center, North-East, and South macro-areas (see Table 1 and 2). Macroareas North-West and Islands did not have a sufficient number of P.1 cases. Data from Marche were excluded due to heterogeneity in data collection. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. ; Prevalence of variants of concern in Italy, February 18 and March 18. During the first genomic survey conducted on February 18, 1,296 samples were sequenced, of which 57 (4%) were discarded for the analysis due to insufficient sequencing coverage of the genome. Among the remaining 1,239 samples, 658 infections were attributable to the SARS-CoV-2 lineage B.1.1.7, 62 to lineage P.1 and 6 to lineage B.1.351, for a national prevalence of 53.1% (95%CI: 50.3-55.9), 5.0% (96%CI: 3.9-6.4) and 0.5% (95%CI: 0.2-1.1), respectively. B.1.1.7 was found in 20 of 21 regions/AP, P.1 in 6, and B.1.351 in 3, as shown in Figure 1 and Table 1 . The prevalence of B.1.1.7 was highest in the North-West macro-area (60.4%, 95%CI: 54.9-65.8%) and lowest in the Center (44.7%, 95%CI: 39.0-50.4), while P.1 was almost exclusively concentrated in the Center (mean prevalence 18.8%, 95%CI: 14.6-23.6, as opposed to 1% or less elsewhere; see Table 1 and Figure 1 ). B.1.351 was identified only in Lombardy (3 cases), in the AP Bolzano (2 cases) and in Sicily (1 case). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. ; During the second genomic survey conducted on March 18, 1,938 samples were sequenced (not including data from Marche), of which 24 (1%) were discarded for the analysis due to lack of enough coverage of the genome sequencing ( 4 .8% (95%CI: 3.9-5.9) and 0.2% (95%CI: 0.0-0.4%), respectively. B.1.1.7 was found in all 21 regions/AP, P.1 in 12, and B.1.351 in 3, as shown in Figure 1 and Table 2 . According to the survey conducted on March 18, B.1.1.7 has become dominant in all Italian regions, with regional prevalence estimates ranging from 63.6% to 100% ( Figure 1 and Table 2 ). Regional prevalence estimates of P.1 range from 0% to 32%; the highest prevalence estimates are still obtained for central regions (Figure 1 ), however, this lineage has been detected in six additional regions compared to February 18. B.1.351 was identified only in Lombardy, Sardinia and Veneto (1 case each). Relative transmissibility of B.1.1.7 and P.1. The model was able to fit the epidemiological trends on hospital admissions and the estimated prevalence of B.1.1.7 and P.1 in all geographical aggregations and independently of the assumed degree of cross-protection. Figure 2 shows results for Italy when assuming no cross-protection or complete cross-protection. Independently on the geographical aggregation and on the assumed degree of crossprotections, we found a robust mean estimate for the relative transmissibility of B.1.1.7, ranging between 1.48 and 1.73, with confidence intervals ranging between 1.31 and 1.97 ( Figure 3 ). Considering the national aggregation, estimates varied between 1.55 and 1.57 with confidence intervals ranging between 1.45 and 1.66. The estimated relative transmissibility of P.1 was systematically lower. For the national aggregation and for the three regions of the macro-area "Center" (Lazio, Tuscany and Umbria) where the observed prevalence of P.1 was higher, we estimate a relative transmissibility of 1.12-1.24 under the assumption of no cross-protection (range of 95% CI: 1.03 -1.42), growing linearly for increasing values of cross-protection, up to 1.39-1.46 (range of 95% CI: 1.26-1.63) under the assumption of complete cross-protection. Results for macro-areas North-East and South reproduce a similar pattern, although estimates are more variable due to the limited number of reported P.1 cases. Based on two genomic surveillance surveys conducted over the whole Italian territory on is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. ; https://doi.org/10.1101/2021.04.06.21254923 doi: medRxiv preprint 1.45 and 1.66) in Italy. These values are consistent with available estimates from UK [1, 2] and France [12] . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. ; broad (between 1.03 and 2.87), with an estimate of cross-protection between 12 and 90%. The true degree of cross-protection between B.1.1.7 and P.1 is likely critical for the coexistence of B.1.1.7 or P.1, and a key role will be played by the effectiveness of licensed vaccines against the two strains. Importantly, the slight decrease of P.1 prevalence over one month occurred under a condition of strict mitigation measures; if P.1 can at least partially escape immunity from B.1.1.7 and existing vaccines, this may pose challenges towards releasing physical distancing measures as population immunity grows. Furthermore, if some degree of crossprotection exists, a higher proportion of asymptomatic infections may be observed, posing challenges to surveillance and control. We acknowledge a number of limitations for this study. The sample size was calculated to have the statistical power to detect different lineages at the macro-area level. As such, regional estimates of prevalence should be taken with caution due to the small number of sequenced samples. Samples were randomly selected for sequencing among cases diagnosed by the labs, but some degree of correlation between them (e.g., cases belonging to an over-represented cluster on that day) cannot be completely excluded, especially in regions with lower sample sizes. Due to the different laboratory methodology of one region in the second survey, those data were excluded from the computation of the national prevalence of the variants. Possible biases in the estimate are expected to be minimal, since cases from this region represented only about 1.5% of the total. For what concerns model estimates on transmissibility, we could not take into account possible differences across strains in the duration of viral shedding [28] , age-specific susceptibility or transmissibility [29] , the proportion of asymptomatic individuals and their relative transmissibility [29] , or other major determinants of the transmission dynamics of SARS-CoV-2, due to the lack of available data on the variants. Similarly, we could not distinguish the potential lineage-specific impact of existing mitigation measures in Italy, nor factor in the potential impact of vaccinations. These factors will likely shape the outcome of the epidemiological competition across strains. Despite these limitations, we provide evidence that the P.1 lineage was not able to outcompete B.1.1.7 in Italy in over a month of co-circulation, under existing mitigation measures. We suggest that this may be due to a lower transmissibility of P.1, independently of its ability to re-infect individuals previously infected by historical or wildtype strains. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 7, 2021. ; * Results for Marche are not reported as the regional laboratory followed a different experimental design (see Methods). # The prevalence and totals for Italy and macro-area Center did not include results from Marche . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 7, 2021. ; https://doi.org/10.1101/2021.04.06.21254923 doi: medRxiv preprint Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England European Centre for Disease Prevention and Control. SARS-CoV-2 -increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update -15 B.1.1.7 lineage-United States Local Transmission of SARS-CoV-2 Lineage B. 1.1. 7, Brazil Global report investigating novel coronavirus haplotypes New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Detection of a SARS-CoV-2 variant of concern in South Africa Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y. V1 (B. 1.1. 7, variant of concern 202012/01) in France Antibody evasion by the P.1 strain of SARS-CoV-2 Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature medicine Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. Emerg Infect Dis SARS-CoV-2 Reinfection by the New Variant of Concern (VOC) P.1 in Amazonas, Brazil (2021) Published online Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report Update note on B.1.1.7 severity Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B. 1.351 variant Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera SARS-CoV-2 Variant Classifications and Definitions The early phase of the COVID-19 outbreak in Densely sampled viral trajectories suggest longer duration of acute infection with B. 1.1. 7 variant relative to non-B. 1.1. 7 SARS-CoV-2. medRxiv Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China The Authors thank Francesco Maraglino, Ministry of Health, for supporting coordination activities.